. 2010 Dec 16;4:1–10. doi: 10.2147/JPR.S12866

Table 3.

Efficacy of duloxetine in treating neuropathic pain

Study duration	Study
	Goldstein et al³⁶				Wernicki et al³⁸			Raskin et al³⁷
	12 weeks				12 weeks			12 weeks
Demographics
Percentage female	38.5				38.9			53.4
Mean age (years)	60.1				60.7			58.8
Treatment group	DLX 20 mg	DLX 60 mg	DLX 120 mg	PBO	DLX 60 mg	DLX 120 mg	PBO	DLX 60 mg	DLX 120 mg	PBO
n	115	114	113	115	114	112	108	116	116	116
Outcome measure (change from baseline ± SE)
24-hour average pain	−2.36 (0.21)	−2.89 (0.22)	−3.24 (0.23)	−1.91 (0.22)	−2.72 (0.22)^*	−2.84 (0.23)^*	−1.39 (0.23)	−2.50 (0.18)^*	−2.47 (0.18)^*	−1.60 (0.18)
24-hour worst pain	−2.78 (0.23)	−3.31 (0.24)^*	−3.72 (0.24)^*	−2.09(0.24)	−3.21 (0.25)^*	−3.39 (0.26)^*	−1.94 (0.25)	−2.97 (0.20)^*	−2.84 (0.20)^*	−2.03 (0.20)
Brief pain inventory
Average pain	−2.25 (0.21)	−2.81 (0.21)^*	−3.07 (0.22)^*	−2.04 (0.21)	−2.66 (0.23)^*	−3.05 (0.24)^*	−1.48 (0.23)	−2.65 (0.19)^*	−2.62 (0.19)^*	−1.82 (0.19)
Worst pain	–	–	–	–	−3.33 (0.27)^*	−3.50 (0.28)^*	−1.98 (0.28)	−3.00 (0.22)	−3.09 (0.22)^*	−2.20 (0.22)
Least pain	–	–	–	–	−1.88 (0.22)^*	−2.30 (0.22)^*	−0.86 (0.22)	−1.98 (0.18)^*	−1.86 (0.18)^*	−1.17 (0.18)
CGI -S	−1.28 (0.11)^*	−1.42 (0.12)^*	−1.7 (0.12)^*	−0.83 (0.12)	−1.37 (0.11)^*	−1.47 (0.12)^*	−0.98 (0.12)	−1.42 (0.09)^*	−1.40 (0.10)^*	−0.93 (0.09)
PGI -I	2.68 (0.12)	2.21 (0.12)^*	2.24 (0.12)^*	2.91 (0.12)	2.61 (1.44)^*	2.40 (1.29)^*	3.17 (1.44)	2.50 (0.10)^*	2.54 (0.10)^*	3.04 (0.10)

Note: Results were statistically significant (P < 0.05) versus placebo.

Abbreviations: DLX, duloxetine; PBO, placebo; FIQ, Fibromyalgia Impact Questionnaire; CGI-I, Clinical Global Impressions of Severity; PGI-I, Patient’s Global Impressions of Improvement; SE, standard error.